NCT06933277 Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
| NCT ID | NCT06933277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 159 participants |
| Start Date | 2025-08-29 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 159 participants in total. It began in 2025-08-29 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
Eligibility Criteria
Inclusion Criteria: * Age equal to or greater than 18 years old at the time of SVd initiation * Signed informed consent (if applicable). * Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria. * Relapse after one to three lines of therapy. * Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization) * Prior treatment with and refractoriness to lenalidomide. Exclusion Criteria: \- Previous exposure to selinexor.
Contact & Investigator
Elena Zamagni
PRINCIPAL INVESTIGATOR
UOC di Ematologia Policlinico S.Orsola AOU di Bologna
Frequently Asked Questions
Who can join the NCT06933277 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06933277 currently recruiting?
Yes, NCT06933277 is actively recruiting participants. Contact the research team at p.fazi@gimema.it for enrollment information.
Where is the NCT06933277 trial being conducted?
This trial is being conducted at Florence, Italy.
Who is sponsoring the NCT06933277 clinical trial?
NCT06933277 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. The principal investigator is Elena Zamagni at UOC di Ematologia Policlinico S.Orsola AOU di Bologna. The trial plans to enroll 159 participants.